Charles River Feb 3, 2026 Charles River to close cell therapy CDMO site, lay off 20 staffers - Fierce Biotech
Sysmex Feb 3, 2026 Improving Coagulation Result Integrity with the Sysmex CS-2500 - Clinical Lab Products
Harvard Bioscience Feb 3, 2026 Harvard Bioscience will move Holliston MA manufacturing out of state - MetroWest Daily News
Illumina Feb 3, 2026 Mapping the future of whole-genome sequencing with Illumina constellation technology - Illumina
Agilent Feb 3, 2026 Monash Innovation Labs and Agilent partner to strengthen applied research in Australia - BioSpectrum Asia
Thermo Fisher Feb 3, 2026 Thermo Fisher Scientific (TMO) Is Down 7.2% After Stronger‑Than‑Expected 2025 Earnings Beat Expectations - What's Changed - simplywall.st
Agilent Feb 3, 2026 Agilent Technologies, Inc. (A) Stock Analysis: Potential 26.76% Upside Raises Investor Optimism - DirectorsTalk Interviews
eLife Feb 3, 2026 Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment
eLife Feb 3, 2026 The chromatin remodeller CHD4 regulates transcription factor binding to both prevent activation of silent enhancers and maintain active regulatory elements